Stanley-Laman Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Stanley-Laman Group's NBIX Position: Q3 2026 in Review
Stanley-Laman Group reduced its Neurocrine Biosciences (NBIX) stake by 2.4% in Q3 2026, selling an estimated $105K and leaving 26,792 shares worth $3.8M. The position accounts for 0.42% of the portfolio, ranked #82.
Stanley-Laman Group first reported a position in NBIX in Q3 2017 and has held it in 14 quarters since. The position peaked at $8.83M in Q2 2018. 770 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Stanley-Laman Group held 26,792 shares of Neurocrine Biosciences worth $3.8M as of Q3 2026.
- Stanley-Laman Group sold 654 Neurocrine Biosciences shares in Q3 2026, an estimated $105K.
- Neurocrine Biosciences made up 0.42% of Stanley-Laman Group's portfolio in Q3 2026, its #82 holding.
- Stanley-Laman Group first reported a position in Neurocrine Biosciences in Q3 2017 and has held it in 14 quarters since.
- Stanley-Laman Group's Neurocrine Biosciences position peaked at $8.83M in Q2 2018.
- 770 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Stanley-Laman Group's 13F filing for Q3 2026, filed 20 Oct 2026.